Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02605811 : Temozolomide in Preventing Brain Metastases in Small Cell Lung Cancer
PhasePhase 2
AgesMin: 18 Years Max: 75 Years
Inclusion Criteria:

1. Histological or cytological diagnosis of small-cll lung cancer histology

2. 18 years or older

3. Eastern Cooperative Oncology Group (ECOG) Performance Status no more than 2

4. Local stage SCLC without distant metastases

5. After 1st-line chemotherapy (EP or IP) at least 4 cycles

6. After radical radiotherapy for primary tumor and lymph node drainage area:including
concurrent or sequence chemoradiotherapy

7. CR or PR assessment by RECIST(1.0) before randomized

8. Haemoglobin 10.0 g/dl, Absolute neutrophil count (ANC) 1.5^9/L, platelets 100 x

9. Total bilirubin 1.5 x upper limit of normal (ULN) alanine aminotransferase (ALT) and
aspartate aminotransferase (AST) < 2.5 x ULN in the absence of liver metastases, or <
5 x ULN in case of liver metastases

10. Creatinine clearance 60ml/min (calculated according to Cockcroft-gault formula)

Exclusion Criteria:

1. Mixed non-small cell lung cancer histology

2. Neck and supraclavicular lymph node metastasis

3. Be allergic to temozolomide or intolerable to radiotherapy

4. Any unstable systemic disease

5. Pregnant or lactating women
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557